ORCHPHARMA1,010.00

Orchid Pharma Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersFDCGUJTHEMIOLCPMOREPENLABRPGLIFEGUFICBIOINNOVACAPUNICHEMLABMcap ₹5,123 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations819.4921.9811.3942.6
Other Income30.927.535.225.6
Total Income850.2949.4846.5968.1
Expenses
+ Cost of Materials Consumed528.4585.5462.3558.6
+ Purchases of Stock-in-Trade0.02.61.71.5
+ Changes in Inventories-43.9-43.961.971.2
+ Employee Benefit Expense69.686.491.597.9
+ Finance Costs16.414.513.312.2
+ Depreciation & Amortisation33.234.535.537.7
+ Other Expenses154.6174.2152.9172.4
Total Expenses758.3853.8818.9951.6
EBITDA110.7117.241.141.0
EBIT77.482.65.73.2
Profit
PBT before Exceptional Items91.995.627.616.5
+ Exceptional Items0.00.0-6.6-6.6
Pretax Income91.995.621.010.0
+ Current Tax0.10.00.00.0
+ Deferred Tax-3.2-0.2-0.20.1
Tax Expense-3.1-0.2-0.20.1
+ Share of Associates & JVs-2.93.9-0.7-1.2
Net Income92.299.720.58.7
+ Net Income — Continuing Ops95.195.821.29.9
+ Other Comprehensive Income-0.3-0.80.91.1
Total Comprehensive Income91.898.921.49.7
Per Share
Basic EPS19.0619.654.051.61
Diluted EPS19.0619.654.051.61
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs2.90.00.0
Other Comprehensive Income — detail
+ Other Comprehensive Income-0.80.91.1
+ Items NOT to be Reclassified to P&L-0.3-0.80.91.1
Per Share — as-filed variants
Basic EPS — Continuing Operations19.0619.654.051.61
Diluted EPS — Continuing Operations19.0619.654.051.61
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit334.9377.7285.5311.3
Gross Margin %40.8740.9735.1833.02
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)91.995.627.616.5
− Exceptional Items (reconciliation)0.00.0-6.6-6.6
Net Income Adj (tax-effected)92.299.727.115.2
EPS Adj19.0619.655.352.82
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital50.750.750.759.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.